Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.77 |
| ▸ | ICMT | O60725 | 13/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | FNTA | P49354 | 3/20 | 0.58 |
| ▸ | FNTB | P49356 | 3/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1814592 | 1.00 | MAPT (0.77) | MAPTALDH1A1ICMTMEN1TRPA1 | |
| SCHEMBL18739961 | 1.00 | MAPT (0.77) | MAPTALDH1A1ICMTMEN1TRPA1 | |
| SCHEMBL14328063 | 1.00 | MAPT (0.77) | MAPTALDH1A1ICMTMEN1TRPA1 | |
| SCHEMBL18298108 | 1.00 | MAPT (0.77) | MAPTALDH1A1ICMTMEN1TRPA1 | |
| SCHEMBL1814594 | 1.00 | MAPT (0.77) | MAPTALDH1A1ICMTMEN1TRPA1 | |
| SCHEMBL2821553 | 0.99 | MAPT (0.76) | MAPTALDH1A1ICMTMEN1TRPA1 | |
| SCHEMBL21045073 | 0.99 | MAPT (0.76) | MAPTALDH1A1ICMTMEN1TRPA1 | |
| SCHEMBL2821551 | 0.99 | MAPT (0.76) | MAPTALDH1A1ICMTMEN1TRPA1 | |
| SCHEMBL3424545 | 0.93 | MAPT (0.74) | MAPTALDH1A1ICMTMEN1TRPA1 | |
| SCHEMBL20218633 | 0.93 | MAPT (0.74) | MAPTALDH1A1ICMTMEN1TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200179319-A1 | PHARMACEUTICAL FORMULATIONS AND THEIR USE | SIGNUM BIOSCIENCES, INC. (US) | 2020-06-11 | — | — | US | claimed |
| US-20190167619-A1 | PHARMACEUTICAL FORMULATIONS AND THEIR USE | SIGNUM BIOSCIENCES, INC. (US) | 2019-06-06 | — | — | US | claimed |
| US-20200179319-A1 | PHARMACEUTICAL FORMULATIONS AND THEIR USE | SIGNUM BIOSCIENCES, INC. (US) | 2020-06-11 | — | — | US | disclosed |
| US-20200179319-A1 | PHARMACEUTICAL FORMULATIONS AND THEIR USE | SIGNUM BIOSCIENCES, INC. (US) | 2020-06-11 | — | — | US | disclosed |
| EP-3497080-A1 | PHARMACEUTICAL FORMULATIONS AND THEIR USE | Signum Biosciences, Inc. (US) | 2019-06-19 | — | — | EP | disclosed |
| US-20190167619-A1 | PHARMACEUTICAL FORMULATIONS AND THEIR USE | SIGNUM BIOSCIENCES, INC. (US) | 2019-06-06 | — | — | US | disclosed |
| US-20190167619-A1 | PHARMACEUTICAL FORMULATIONS AND THEIR USE | SIGNUM BIOSCIENCES, INC. (US) | 2019-06-06 | — | — | US | disclosed |
| WO-2018031571-A1 | PHARMACEUTICAL FORMULATIONS AND THEIR USE | SIGNUM BIOSCIENCES, INC. (US) | 2018-02-15 | — | — | WO | disclosed |
| WO-2018031427-A1 | PHARMACEUTICAL FORMULATIONS AND THEIR USE | DERMATA THERAPEUTICS, LLC (US) | 2018-02-15 | — | — | WO | disclosed |
| WO-2018031427-A1 | PHARMACEUTICAL FORMULATIONS AND THEIR USE | DERMATA THERAPEUTICS, LLC (US) | 2018-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190167619-A1 | PHARMACEUTICAL FORMULATIONS AND THEIR USE | LIPE, LIPA, FASN | MAPT 1433/4885ALDH1A1 4159/4885ICMT 155/4885 |
| US-20200179319-A1 | PHARMACEUTICAL FORMULATIONS AND THEIR USE | SLC10A1, SLC6A6, CEL | MAPT 844/4885ALDH1A1 409/4885ICMT 2168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.